ME03351B - Steroidno jedinjenje za upotrebu u lečenju hepatične encefalopatije - Google Patents
Steroidno jedinjenje za upotrebu u lečenju hepatične encefalopatijeInfo
- Publication number
- ME03351B ME03351B MEP-2019-39A MEP201939A ME03351B ME 03351 B ME03351 B ME 03351B ME P201939 A MEP201939 A ME P201939A ME 03351 B ME03351 B ME 03351B
- Authority
- ME
- Montenegro
- Prior art keywords
- treatment
- hepatic encephalopathy
- steroid compound
- steroid
- compound
- Prior art date
Links
- -1 STEROID COMPOUND Chemical class 0.000 title 1
- 208000007386 hepatic encephalopathy Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7016—Disaccharides, e.g. lactose, lactulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Emergency Medicine (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biotechnology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE1450089 | 2014-01-29 | ||
| EP15705691.2A EP3099306B1 (en) | 2014-01-29 | 2015-01-14 | Steroid compound for use in the treatment of hepatic encephalopathy |
| PCT/GB2015/050060 WO2015114308A1 (en) | 2014-01-29 | 2015-01-14 | Steroid compound for use in the treatment of hepatic encephalopathy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ME03351B true ME03351B (me) | 2019-10-20 |
Family
ID=52544513
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MEP-2019-39A ME03351B (me) | 2014-01-29 | 2015-01-14 | Steroidno jedinjenje za upotrebu u lečenju hepatične encefalopatije |
Country Status (25)
| Country | Link |
|---|---|
| US (3) | US20160339040A1 (me) |
| EP (1) | EP3099306B1 (me) |
| JP (1) | JP6543633B2 (me) |
| KR (1) | KR102324667B1 (me) |
| CN (2) | CN113185566A (me) |
| AU (1) | AU2015212606B2 (me) |
| BR (1) | BR112016017620A2 (me) |
| CA (1) | CA2935015C (me) |
| CY (1) | CY1121464T1 (me) |
| DK (1) | DK3099306T3 (me) |
| ES (1) | ES2714563T3 (me) |
| HR (1) | HRP20190251T1 (me) |
| HU (1) | HUE042242T2 (me) |
| IL (1) | IL246496B (me) |
| LT (1) | LT3099306T (me) |
| ME (1) | ME03351B (me) |
| MX (1) | MX2016008851A (me) |
| PL (1) | PL3099306T3 (me) |
| PT (1) | PT3099306T (me) |
| RS (1) | RS58375B1 (me) |
| RU (1) | RU2684616C2 (me) |
| SI (1) | SI3099306T1 (me) |
| SM (1) | SMT201900133T1 (me) |
| TR (1) | TR201901687T4 (me) |
| WO (1) | WO2015114308A1 (me) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2684616C2 (ru) | 2014-01-29 | 2019-04-10 | Умекрин Когнишн Аб | Стероидное соединение для применения в лечении печеночной энцефалопатии |
| TWI748936B (zh) | 2015-01-12 | 2021-12-11 | 瑞典商優鎂奎認知Ａｂ公司 | 新穎化合物 |
| US10278977B2 (en) | 2016-06-06 | 2019-05-07 | Umecrine Cognition Ab | Methods for treating hypersomnolence |
| JP7203438B2 (ja) | 2017-09-12 | 2023-01-13 | イーティーエイチ・チューリッヒ | 体液中アンモニア定量用の膜貫通ｐＨ勾配ポリマーソーム |
| BR112020010519A2 (pt) * | 2017-11-27 | 2020-10-20 | Umecrine Cognition Ab | formulação farmacêutica de oxima de 3¿lfa-etinil-3¿eta-hidroxiandrostan-17-ona |
| EP4079307A1 (en) * | 2021-04-20 | 2022-10-26 | Umecrine Cognition AB | New medical use |
| US20230134958A1 (en) * | 2021-10-29 | 2023-05-04 | Umecrine Cognition Ab | New medical treatment |
| EP4389129A1 (en) | 2022-12-22 | 2024-06-26 | Umecrine Cognition AB | 3a-ethynyl-3beta hydroxyandrostan 17-one oxime for treating parkinson's disease and l-dopa-induced dyskinesia |
| WO2025252724A1 (en) | 2024-06-04 | 2025-12-11 | Umecrine Cognition Ab | Novel pharmaceutical formulation of golexanolone |
| WO2025252725A1 (en) | 2024-06-04 | 2025-12-11 | Umecrine Cognition Ab | Novel pharmaceutical formulation of golexanolone |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2713061A (en) | 1951-04-06 | 1955-07-12 | Schering Ag | 3-methyl androstanes |
| FR1463755A (fr) | 1960-01-26 | 1966-07-22 | Nouveaux stéroïdes de la série de l'androstane et leur procédé de préparation | |
| US3173932A (en) | 1962-11-02 | 1965-03-16 | American Cyanamid Co | 15-substituted estra-1, 3, 5(10)-trienes |
| FR2685332A1 (fr) | 1991-12-20 | 1993-06-25 | Roussel Uclaf | Nouveaux 19-nor sterouides ayant en position 11beta une chaine thiocarbonee, leur procede de preparation et les intermediaires et leur application a titre de medicaments. |
| AU698834B2 (en) | 1993-05-24 | 1998-11-12 | Purdue Pharma Ltd. | Methods and compositions for inducing sleep |
| CA2321728C (en) | 1998-03-11 | 2008-12-09 | Torbjorn Backstrom | Epiallopregnanolone in the treatment of cns disorders |
| WO2002100877A1 (en) | 2001-06-11 | 2002-12-19 | Southwest Foundation For Biomedical Research | Novel 2-alkoxyestradiol analogs with antiproliferative and antimitotic activity |
| GB0129260D0 (en) * | 2001-12-06 | 2002-01-23 | Eisai London Res Lab Ltd | Pharmaceutical compositions and their uses |
| SE0104423D0 (sv) | 2001-12-27 | 2001-12-27 | Umecrine Ab | Pregnane steroids and their use in the treatment of CNS disorders |
| PL1824563T3 (pl) | 2004-11-26 | 2010-07-30 | Ucl Business Plc | Kompozycje zawierające ornitynę i fenylooctan lub fenylomaślan do leczenia encefalopatii wątrobowej |
| WO2007103162A2 (en) * | 2006-03-01 | 2007-09-13 | Samaritan Pharmaceuticals, Inc. | Structure based drug design of steroidogenesis inhibitors |
| ES2607852T3 (es) * | 2006-11-21 | 2017-04-04 | Umecrine Ab | El uso de esteroides de pregnano y androstano para la fabricación de una composición farmacéutica para el tratamiento de trastornos del SNC |
| GB0711948D0 (en) | 2007-06-20 | 2007-08-01 | Bionature E A Ltd | Neurosteriod compounds |
| CN101585862B (zh) * | 2008-05-20 | 2014-12-17 | 梅克芳股份公司 | 甾族化合物 |
| EP2350096B1 (en) * | 2008-10-02 | 2019-12-11 | Salix Pharmaceuticals, Ltd. | Methods of treating hepatic encephalopathy |
| JP5749255B2 (ja) | 2009-06-08 | 2015-07-15 | ユーシーエル ビジネス ピーエルシー | Ｌ−オルニチンフェニル酢酸塩を用いる門脈圧亢進の治療及び肝機能の修復 |
| WO2015048818A1 (en) | 2013-09-30 | 2015-04-02 | Hyperion Therapeutics, Inc. | Diagnosing, grading, monitoring, and treating hepatic encephalopathy |
| RU2684616C2 (ru) | 2014-01-29 | 2019-04-10 | Умекрин Когнишн Аб | Стероидное соединение для применения в лечении печеночной энцефалопатии |
-
2015
- 2015-01-14 RU RU2016127558A patent/RU2684616C2/ru active
- 2015-01-14 BR BR112016017620A patent/BR112016017620A2/pt not_active Application Discontinuation
- 2015-01-14 HU HUE15705691A patent/HUE042242T2/hu unknown
- 2015-01-14 WO PCT/GB2015/050060 patent/WO2015114308A1/en not_active Ceased
- 2015-01-14 SI SI201530591T patent/SI3099306T1/sl unknown
- 2015-01-14 RS RS20190234A patent/RS58375B1/sr unknown
- 2015-01-14 PL PL15705691T patent/PL3099306T3/pl unknown
- 2015-01-14 KR KR1020167023426A patent/KR102324667B1/ko active Active
- 2015-01-14 CN CN202110480203.5A patent/CN113185566A/zh active Pending
- 2015-01-14 SM SM20190133T patent/SMT201900133T1/it unknown
- 2015-01-14 PT PT15705691T patent/PT3099306T/pt unknown
- 2015-01-14 EP EP15705691.2A patent/EP3099306B1/en active Active
- 2015-01-14 ME MEP-2019-39A patent/ME03351B/me unknown
- 2015-01-14 HR HRP20190251TT patent/HRP20190251T1/hr unknown
- 2015-01-14 CA CA2935015A patent/CA2935015C/en active Active
- 2015-01-14 US US15/114,972 patent/US20160339040A1/en not_active Abandoned
- 2015-01-14 LT LTEP15705691.2T patent/LT3099306T/lt unknown
- 2015-01-14 TR TR2019/01687T patent/TR201901687T4/tr unknown
- 2015-01-14 CN CN201580006600.1A patent/CN106163528A/zh active Pending
- 2015-01-14 AU AU2015212606A patent/AU2015212606B2/en active Active
- 2015-01-14 JP JP2016544557A patent/JP6543633B2/ja active Active
- 2015-01-14 DK DK15705691.2T patent/DK3099306T3/en active
- 2015-01-14 MX MX2016008851A patent/MX2016008851A/es active IP Right Grant
- 2015-01-14 ES ES15705691T patent/ES2714563T3/es active Active
-
2016
- 2016-06-28 IL IL246496A patent/IL246496B/en active IP Right Grant
- 2016-11-15 US US15/352,035 patent/US9801894B2/en active Active
-
2017
- 2017-09-27 US US15/716,838 patent/US10342804B2/en active Active
-
2019
- 2019-03-12 CY CY20191100299T patent/CY1121464T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ME03351B (me) | Steroidno jedinjenje za upotrebu u lečenju hepatične encefalopatije | |
| MA49760A (fr) | Mavacamten destiné à être utilisé dans le traitement de la cardiomyopathie hypertrophique | |
| EP3558313A4 (en) | SUBSTANCES FOR TREATING CONDITIONS RELATING TO FATTY LIVER | |
| DK3481846T3 (da) | 11-substituerede 24-hydroxysteroler til anvendelse til behandling af nmda-relaterede tilstande | |
| DK4374873T3 (da) | Middel til brug ved behandling eller forebyggelse af oftalmologiske tilstande | |
| EP3299002A4 (en) | walking assistance device | |
| EP3380643A4 (en) | PRE-COATED GUARD FOR VHF RF PVD CHAMBERS | |
| DK3192518T3 (da) | Anti-inflammatorisk middel | |
| EP3389665A4 (en) | METAL-COMPLEXED THERAPEUTICS AND NANOPARTICLE FORMULATIONS ON LIPID BASIS THEREOF | |
| EP3267987A4 (en) | CHEMICALLY MODIFIED CLUROMES FOR USE IN THE PREPARATION OF LIPOXINES | |
| EP3378606A4 (en) | AUXILIARY SET | |
| MA46608A (fr) | Formulation liposomale destinée à être utilisée dans le traitement du cancer | |
| ZA201704957B (en) | Composition for the treatment of hepatic veno-occlusive disease | |
| EP3848022C0 (en) | THERAPEUTIC AGENT FOR USE IN THE TREATMENT OF INFECTION | |
| MA47111A (fr) | Agents ciblant sirpgamma destinés à être utilisés dans le traitement du cancer | |
| MA45848A (fr) | Cobicistat destiné à être utilisé dans des traitements du cancer | |
| EP3530722A4 (en) | DETERGENT COMPOSITION | |
| MA43106A (fr) | Traitement de l'oligo-ovulation associée à la stéatose hepatique | |
| EP3114197C0 (en) | DETERGENT COMPOSITION WITH CLEANING AND RINSEING FUNCTIONS | |
| DK3096775T5 (da) | SOCS-mimetika til behandling af sygdomme | |
| EP3404017A4 (en) | FLUOROMATED CONNECTION AND USE THEREOF | |
| EP3406258A4 (en) | MEDICINAL PRODUCT FOR USE IN THE TREATMENT OF GICHT | |
| EP3337784A4 (en) | USE OF UREIDOMUSTIN (BO-1055) IN CANCER TREATMENT | |
| EP3349731A4 (en) | COMBINATION OF TOPOISOMERASE I INHIBITORS WITH IMMUNOTHERAPY IN THE TREATMENT OF CANCER | |
| EP3694391A4 (en) | DEVICE FOR USE IN THE TREATMENT OF HEMORRHOIDS |